Statins for Patients With Non-Alcoholic Fatty Liver Disease

Talal Shakas AlGhamdi

Abstract


Non-alcoholic fatty liver disease (NAFLD) commonly causes an increase in the transaminase levels with the underlying problems, including diabetes, obesity, or both. NAFLD patients are often at an increased risk of cardiovascular events globally, representing a leading cause of death. Therefore, this study aims to review present evidence regarding the utilization of statin in NAFLD patients and discuss the effects of these agents on liver histology and cardiovascular disease. We comprehensively reviewed the current evidence on the statins safety in NAFLD patients and their effects on cardiovascular events or liver histology. The findings suggest that statins are safe to be administered to NAFLD patients including people with increased transaminase (< 3 times - upper limit of normal). The reviewed studies indicate that statins may reduce cardiovascular risk. Some controversial data also emerged from the literature regarding the effect of statins on liver histology in NAFLD patients. The treatment with statins is safe, which may also lessen cardiovascular events in patients with NAFLD. Future and ongoing studies will elucidate if statins have a role in treating NAFLD. Although clinicians are often refrained from prescribing statins for NAFLD patients, it is used to reduce cardiovascular mortality and morbidity and lower liver enzymes.




J Endocrinol Metab. 2020;10(6):162-166
doi: https://doi.org/10.14740/jem705

Keywords


Hydroxymethylglutaryl-CoA reductase inhibitors; Non-alcoholic steatohepatitis; Atorvastatin; Statins

Full Text: HTML PDF
 

Browse  Journals  

 

Journal of Clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics

 

World Journal of Oncology

Gastroenterology Research

Journal of Hematology

 

Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity

 

Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research

 

Journal of Neurology Research

International Journal of Clinical Pediatrics

 

 
       
 

Journal of Endocrinology and Metabolism, bimonthly, ISSN 1923-2861 (print), 1923-287X (online), published by Elmer Press Inc.                     
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)


This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.jofem.org   editorial contact: editor@jofem.org    elmer.editorial2@hotmail.com
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.


Disclaimer: The views and opinions expressed in the published articles are those of the authors and do not necessarily reflect the views or opinions of the editors and Elmer Press Inc. This website is provided for medical research and informational purposes only and does not constitute any medical advice or professional services. The information provided in this journal should not be used for diagnosis and treatment, those seeking medical advice should always consult with a licensed physician.